Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 24, Art. 69 (pp. 1021-1032)    |    2023       

»

Induction therapy and survival of multiple myeloma patients after autological hematopoietic stem cell transplantation

Kostroma I.I.1, Yudina V.A.1,2, Romanenko N.A.1, Stepchenkova E.I.3,4, Sidorova Zh.Yu.5, Bessmeltsev S.S.1, Sidorkevich S.V.1, Gritsaev S.V.1

1FGBU "Russian Research Institute of Hematology and Transfusiology of the Federal Medical and Biological Agency of Russia", 191024, St. Petersburg, Russia
2FGBU "National Medical Center named after N.N. V. A. Almazov» Ministry of Health of Russia, 197341, St. Petersburg, Russia
3FGBOU VO "St. Petersburg State University", 199034, St. Petersburg, Russia
4FGBUN "Institute of General Genetics. N.I. Vavilov RAS, St. Petersburg branch, 199034, St. Petersburg, Russia
5FGBU Petersburg Nuclear Physics Institute named by B.P.Konstantinov of NRC «Kurchatov Institute», 188300, Leningradskaya Oblast, Russia

Brief summary

Autologous hematopoietic stem cell transplantation (AutoHSCT) is a step in the treatment of patients with multiple myeloma (MM), who, according to their comorbidity status, may be candidates for high-dose chemotherapy. The effectiveness of AutoHSCT depends on many factors, including the intensity of the conditioning regimen and the response in the post-transplant period. Many authors dispute the value of the answer option immediately before AutoHSCT. According to the results of the retrospective study, there was no significant difference in the median of progressive and overall survival of patients with MM, depending on the type of drugs prescribed during the induction period. At the same time, an analysis of the frequency of individual response options before AutoHSCT, together with the need to change therapy to achieve at least a partial response, and the nature of the therapeutic benefit prescribed for this, made it possible to conclude that an early transfer to reserve combinations of drugs is expedient.


Key words

multiple myeloma, autologous hematopoietic stem cell transplantation, response variant, survival

Reference list

1.Aksenova A.Y., Zhuk A.S., Lada A.G. et al. Genome instability in multiple myeloma: facts and factors. Cancers. 2021; 13: 5949. https://doi.org/10.3390/cancers13235949.


2. Bessmelcev S.S., Abdylkadirov K.M. Mnojestvennaya mieloma: rykovodstvo dlya vrachei. M.: MK; 2016; 516 s.


3. Bessmelcev SS. Mnojestvennaya mieloma: diagnostika i terapiya (chast 1). Vestnik gematologii. 2022; 2: 4-26.


4. Bessmelcev SS. Mnojestvennaya mieloma: diagnostika i terapiya (chast 2). Vestnik gematologii. 2022; 3: 4-31.


5. Rajkumar S. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022; 97: 1086-1107. https://doi.org/10.1002/ajh.26590.


6. Dimopoulos M.A., Moreau P., Terpos E. et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021; 5: e528. https://doi.org/10.1097/HS9.0000000000000528.


7. Cavo M., Gay F., Beksac M. et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020; 7: e456-e468. https://doi.org/10.1016/S2352-3026(20)30099-5.


8. Voorhees P.M., Rodriguez C., Reeves B. et al. Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. Blood Adv. 2021; 5: 1092-1096. https://doi.org/10.1182/bloodadvances.2020003642.


9. Attal M., Lauwers-Cances V., Hulin C. et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017; 376: 1311-1320. https://doi.org/10.1056/NEJMoa1611750.


10. Kwee Y., William W., de Tute R. et al. Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial. Lancet Haematol. 2023; 10: e93-e106. https://doi.org/10.1016/S2352-3026(22)00350-7.


11. Gay F., Musto P., Rota-Scalabrini D. et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021; 22: 1705-1720. https://doi.org/10.1016/S1470-2045(21)00535-0.


12. Richardson P., Jacobus S., Weller E. et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022; 387:132-147. https://doi.org/10.1056/NEJMoa2204925.


13. Aggarwal M., Agrawal N., Yadav N. et al. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma. Ann Hematol. 2018; 97: 1869-1877. https://doi.org/10.1007/s00277-018-3370-1.


14. Zhang B.L., Zhou J., Lin Q.D. et al. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma. Artif Organs. 2019; 43:1028-1034. https://doi.org/10.1111/aor.13468.


15. Zhou H., Jian Y., Du J. et al. Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era. Cancer Med. 2023. https://doi.org/10.1002/cam4.5630.


16. Goswami C, Poonia S, Kumar L, et al. Staging system to predict the risk of relapse in multiple myeloma patients undergoing autologous stem cell transplantation. Front Oncol. 2019; 9: 633. https://doi.org/10.3389/fonc.2019.00633.


17. Harousseau J.L., Avet-Loiseau H., Attal M. et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 trials. J Clin Oncol. 2009; 27: 5720-5726. https://doi.org/10.1200/JCO.2008.21.1060.


18. Kostroma I.I., Sidorova J.U., Semenova N.U. i dr. Vozmojnie prediktori i kachestvo otveta posle transplantacii aytologichnih gemopoeticheskih stvolovih kletok pri mnojestvennoi mielome. Klinicheskaya onkogematologiya. 2021; 3: 333-339. https://doi.org/ 10.21320/2500-2139-2021-14-3-333-339.


19. Kumar S., Paiva B., Anderson K.C. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17: e328-e46. https://doi.org/ doi: 10.1016/S1470-2045(16)30206-6.


20. Moreau P., Attal M., Hulin C. et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019; 394: 29-38. https://doi.org/10.1016/S0140-6736(19)31240-1.


21. Byun J.M., Park S.S., Yoon S.S. et al. Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study. Blood Res. 2023. https://doi.org/10.5045/br.2023.2023005.


22. Gagelmann N., Eikema D.J., Koster L. et al. Tandem autologous stem cell transplantation improves outcomes in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the chronic malignancies working party of the european society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2019; 25: 2134-2142. https://doi.org/10.1016/j.bbmt.2019.07.004.


23. Stadtmauer E., Pasquini M., Blackwell B. et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial. J Clin Oncol. 2019; 37: 589-597. https://doi.org/10.1200/JCO.18.00685.


24. Kumar L., Sahoo R., Kumar S. et al. Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome. Leuk Lymphoma. 2023; 64: 378-387. https://doi.org/10.1080/10428194.2022.2148214.


25. Kostroma I.I., Jyk A.S., Sidorova J.U. i dr. Effektivnost rejimov kombinirovannoi lekarstvennoi predtransplantacionnoi podgotovki y pacientov s odnokratnoi transplantaciei aytologichnih gemopoeticheskih stvolovih kletok pri mnojestvennoi mielome. Klinicheskaya onkogematologiya. 2023; 16: 88-95. https://doi.org/10.21320/2500-2139-2023-16-1-88-95.


26. Moreau P., Cyrille H., Aurore P. et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22: 1378-1390. https://doi.org/10.1016/S1470-2045(21)00428-9.


27. Pasvolsky O., Milton D., Rauf M. et al. Lenalidomide-based maintenance after autologous hematopoietic stem cell transplantation for patients with high-risk multiple myeloma. Transplant Cell Ther. 2022; 28: 752.e1-752.e6. https://doi.org/10.1016/j.jtct.2022.07.028.


28. Garderet L., Sbianchi G., Iacobelli S. et al. Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT. Eur J Haematol. 2021; 106: 708-715. https://doi.org/10.1111/ejh.13602.


29. Girvan A., Yu J., Kamalakar R. et al. Treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma receiving ≥3 lines of therapy: a real-world evaluation in the United States. Blood. 2022; 140 (Suppl 1): 5288-5290. https://doi.org/10.1182/blood-2022-156225.


30. Lee Y., Yoon J., Park B., Eom H.S. Real-world treatment patterns and outcomes of patients with newly diagnosed multiple myeloma: an analysis using National Health Insurance service database. Blood. 2022; 140 (Suppl 1): 5156-5157. https://doi.org/10.1182/blood-2022-157676.